{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T02:55:51Z","timestamp":1792119351087,"version":"4.4.0"},"reference-count":245,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T00:00:00Z","timestamp":1771113600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Antibody\u2013drug conjugates (ADCs) represent a transformative class of targeted therapies designed to deliver potent cytotoxic agents specifically to tumor cells, minimizing systemic toxicity. This review provides a comprehensive overview of ADCs, detailing their mechanisms of action, design strategies, and clinical advancements. ADCs utilize monoclonal antibodies to selectively bind tumor-associated antigens, enabling the precise delivery of toxic payloads to cancer cells. The review explores the critical components of ADCs, including the antibody, linker, and payload, and highlights how these elements can be optimized to improve efficacy and minimize off-target effects. We examine the evolution of ADC design from early constructs to the latest innovations and the development of novel payloads that extend therapeutic possibilities beyond traditional cytotoxic agents. Additionally, we discuss the clinical success of ADCs, with examples from approved therapies such as gemtuzumab ozogamicin, brentuximab vedotin, and trastuzumab emtansine, which have redefined the treatment landscape for various cancers. Despite their success, ADCs face challenges such as tumor heterogeneity, resistance mechanisms, and toxicity, which are actively being addressed through ongoing research. The review concludes with an outlook on the future of ADCs, highlighting emerging strategies in conjugation technology, payload design, and combination therapies that are poised to enhance their therapeutic potential across oncology and other disease areas.<\/jats:p>","DOI":"10.3390\/ph19020324","type":"journal-article","created":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T12:37:28Z","timestamp":1771245448000},"page":"324","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Frontiers in Antibody\u2013Drug Conjugates: Mechanisms, Design Innovations, and Clinical Applications in Targeted Cancer Therapy"],"prefix":"10.3390","volume":"19","author":[{"given":"Xinghan","family":"Li","sequence":"first","affiliation":[{"name":"Department of Stomatology, General Hospital of Northern Theater Command, No. 83, Wenhua Road, Shenhe District, Shenyang 110016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaming","family":"Liu","sequence":"additional","affiliation":[{"name":"Neurosurgery, General Hospital of Northern Theater Command, No. 83, Wenhua Road, Shenhe District, Shenyang 110016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yitong","family":"Meng","sequence":"additional","affiliation":[{"name":"Department of Stomatology, General Hospital of Northern Theater Command, No. 83, Wenhua Road, Shenhe District, Shenyang 110016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Stomatology, General Hospital of Northern Theater Command, No. 83, Wenhua Road, Shenhe District, Shenyang 110016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jieling","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Stomatology, General Hospital of Northern Theater Command, No. 83, Wenhua Road, Shenhe District, Shenyang 110016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-1242-8792","authenticated-orcid":false,"given":"Dequan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Urology, the First Affiliated Hospital of Dalian Medical University, Dalian 116011, China"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaodong","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Stomatology, General Hospital of Northern Theater Command, No. 83, Wenhua Road, Shenhe District, Shenyang 110016, China"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,2,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1038\/s41392-024-01856-7","article-title":"Exploring treatment options in cancer: Tumor treatment strategies","volume":"9","author":"Liu","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/s41573-023-00709-2","article-title":"Antibody-drug conjugates come of age in oncology","volume":"22","author":"Dumontet","year":"2023","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"107917","DOI":"10.1016\/j.pharmthera.2021.107917","article-title":"Stepping forward in antibody-drug conjugate development","volume":"229","author":"Jin","year":"2022","journal-title":"Pharmacol. Ther."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"3297","DOI":"10.1021\/acs.chemrev.0c00383","article-title":"Challenges and Opportunities in Cancer Drug Resistance","volume":"121","author":"Ward","year":"2021","journal-title":"Chem. Rev."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1182\/blood-2004-10-3821","article-title":"Safety and efficacy of gemtuzumab ozogamicin in pediatric patients with advanced CD33+ acute myeloid leukemia","volume":"106","author":"Arceci","year":"2005","journal-title":"Blood"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1056\/NEJMoa1708984","article-title":"Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin\u2019s Lymphoma","volume":"378","author":"Connors","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1056\/NEJMoa1814017","article-title":"Trastuzumab Emtansine for Residual Invasive HER2-Positive Breast Cancer","volume":"380","author":"Huang","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1056\/NEJMoa2203690","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer","volume":"387","author":"Modi","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1038\/s41577-025-01207-9","article-title":"Fifty years of monoclonals: The past, present and future of antibody therapeutics","volume":"25","author":"Chan","year":"2025","journal-title":"Nat. Rev. Immunol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.coph.2018.05.010","article-title":"Monoclonal antibodies as immunomodulatory therapy against cancer and autoimmune diseases","volume":"41","author":"Hafeez","year":"2018","journal-title":"Curr. Opin. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1038\/s41392-022-00947-7","article-title":"Antibody drug conjugate: The \u201cbiological missile\u201d for targeted cancer therapy","volume":"7","author":"Fu","year":"2022","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/0092-8674(78)90099-5","article-title":"One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell","volume":"15","author":"Yamaizumi","year":"1978","journal-title":"Cell"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"McGavin, J.K., and Spencer, C.M. (2001). Gemtuzumab ozogamicin. Drugs, 61, 1317\u20131322, discussion 1323\u20131324.","DOI":"10.2165\/00003495-200161090-00007"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1021\/bc010021y","article-title":"Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia","volume":"13","author":"Hamann","year":"2002","journal-title":"Bioconjug. Chem."},{"key":"ref_15","first-page":"1490","article-title":"Approval summary: Gemtuzumab ozogamicin in relapsed acute myeloid leukemia","volume":"7","author":"Bross","year":"2001","journal-title":"Clin. Cancer Res."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"3197","DOI":"10.1182\/blood-2014-06-537514","article-title":"Brentuximab vedotin","volume":"124","author":"Ansell","year":"2014","journal-title":"Blood"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1783","DOI":"10.1056\/NEJMoa1209124","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma","year":"2012","journal-title":"N. Engl. J. Med."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1007\/s13238-016-0323-0","article-title":"Antibody-drug conjugates: Recent advances in conjugation and linker chemistries","volume":"9","author":"Tsuchikama","year":"2018","journal-title":"Protein Cell"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.apsb.2024.01.009","article-title":"Bispecific antibody drug conjugates: Making 1 + 1 > 2","volume":"14","author":"Gu","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s13045-025-01704-3","article-title":"Antibody-Drug Conjugates (ADCs): Current and future biopharmaceuticals","volume":"18","author":"Wang","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jconrel.2020.03.005","article-title":"Improving antibody-based therapies by chemical engineering of antibodies with multimeric cell-penetrating peptides for elevated intracellular delivery","volume":"322","author":"Sauter","year":"2020","journal-title":"J. Control. Release"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"115161","DOI":"10.1016\/j.colsurfb.2025.115161","article-title":"Antibody-drug conjugates (ADCs): \u201cSmart Missiles\u201d targeting cancer therapy","volume":"257","author":"Yao","year":"2025","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"17588359231183679","DOI":"10.1177\/17588359231183679","article-title":"Antibody-drug conjugates: The evolving field of targeted chemotherapy for breast cancer treatment","volume":"15","author":"Molinelli","year":"2023","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"116522","DOI":"10.1016\/j.biopha.2024.116522","article-title":"Implementation of antibody-drug conjugates in HER2-positive solid cancers: Recent advances and future directions","volume":"174","author":"Yu","year":"2024","journal-title":"Biomed. Pharmacother."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/PPO.0000000000000634","article-title":"Antibody-Drug Conjugates in Breast Cancer: Spotlight on HER2","volume":"28","author":"Abelman","year":"2022","journal-title":"Cancer J."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2492236","DOI":"10.1080\/19420862.2025.2492236","article-title":"The physiological limits of bispecific monoclonal antibody tissue targeting specificity","volume":"17","author":"Sepp","year":"2025","journal-title":"mAbs"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1007\/s11684-024-1072-8","article-title":"Unlocking the potential of bispecific ADCs for targeted cancer therapy","volume":"18","author":"Zeng","year":"2024","journal-title":"Front. Med."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1007\/s12272-023-01433-6","article-title":"Antibody-drug conjugates and bispecific antibodies targeting cancers: Applications of click chemistry","volume":"46","author":"Hong","year":"2023","journal-title":"Arch. Pharm. Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"2441411","DOI":"10.1080\/19420862.2024.2441411","article-title":"A bispecific antibody-drug conjugate targeting pCAD and CDH17 has antitumor activity and improved tumor-specificity","volume":"17","author":"Synan","year":"2025","journal-title":"mAbs"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"De Novellis, D., Fontana, R., Giudice, V., Serio, B., and Selleri, C. (2022). Innovative Anti-CD38 and Anti-BCMA Targeted Therapies in Multiple Myeloma: Mechanisms of Action and Resistance. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24010645"},{"key":"ref_31","first-page":"686","article-title":"Antibody-Drug Conjugate for Treating Leukemia and Lymphoma-The Present Status, Problems, and Future Development","volume":"51","author":"Ida","year":"2024","journal-title":"Gan Kagaku Ryoho"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1021\/acs.bioconjchem.0c00337","article-title":"A Platform for the Generation of Site-Specific Antibody-Drug Conjugates That Allows for Selective Reduction of Engineered Cysteines","volume":"31","author":"Coumans","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1021\/acs.bioconjchem.3c00425","article-title":"Selective Reduction of Cysteine Mutant Antibodies for Site-Specific Antibody-Drug Conjugates","volume":"34","author":"Liao","year":"2023","journal-title":"Bioconjug. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1021\/acs.bioconjchem.0c00061","article-title":"Site-Specific Conjugation of Native Antibodies Using Engineered Microbial Transglutaminases","volume":"31","author":"Dickgiesser","year":"2020","journal-title":"Bioconjug. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1021\/acs.biochem.5c00040","article-title":"Structural Insights into Lipoate Ligase A-Mediated Antibody Modifications","volume":"64","author":"Takahashi","year":"2025","journal-title":"Biochemistry"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2763","DOI":"10.1039\/D4SC06500J","article-title":"Formation of mono- and dual-labelled antibody fragment conjugates via reversible site-selective disulfide modification and proximity induced lysine reactivity","volume":"16","author":"Thanasi","year":"2025","journal-title":"Chem. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"e202402113","DOI":"10.1002\/cbdv.202402113","article-title":"Antibody Modification via Lipoic Acid Ligase A-Mediated Site-Specific Labeling","volume":"22","author":"Yamazaki","year":"2025","journal-title":"Chem. Biodivers."},{"key":"ref_38","first-page":"728","article-title":"AJICAP Second Generation: Improved Chemical Site-Specific Conjugation Technology for Antibody-Drug Conjugate Production","volume":"34","author":"Fujii","year":"2023","journal-title":"Bioconjug. Chem."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"e202400522","DOI":"10.1002\/open.202400522","article-title":"The Impact of Conjugation Mode and Site on Tubulysin Antibody-Drug-Conjugate Efficacy and Stability","volume":"14","author":"Yamazoe","year":"2025","journal-title":"ChemistryOpen"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"121981","DOI":"10.1016\/j.jchromb.2020.121981","article-title":"Proof of site-specificity of antibody-drug conjugates produced by chemical conjugation technology: AJICAP first generation","volume":"1140","author":"Matsuda","year":"2020","journal-title":"J. Chromatogr. B"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"e202202491","DOI":"10.1002\/chem.202202491","article-title":"Chemoselective Methionine Labelling of Recombinant Trastuzumab Shows High In Vitro and In Vivo Tumour Targeting","volume":"29","author":"Hashad","year":"2023","journal-title":"Chemistry"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4058","DOI":"10.1021\/acs.molpharmaceut.1c00473","article-title":"Chemical Site-Specific Conjugation Platform to Improve the Pharmacokinetics and Therapeutic Index of Antibody-Drug Conjugates","volume":"18","author":"Matsuda","year":"2021","journal-title":"Mol. Pharm."},{"key":"ref_43","first-page":"71","article-title":"Dual-mechanistic antibody-drug conjugate via site-specific selenocysteine\/cysteine conjugation","volume":"2","author":"Nilchan","year":"2019","journal-title":"Antib. Ther."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2158","DOI":"10.1021\/acs.bioconjchem.5c00239","article-title":"SPARC: A Multipayload ADC Architecture for Programmable Drug Combinations","volume":"36","author":"Sun","year":"2025","journal-title":"Bioconjug. Chem."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1021\/acs.bioconjchem.1c00134","article-title":"A Simple and Efficient Method to Generate Dual Site-Specific Conjugation ADCs with Cysteine Residue and an Unnatural Amino Acid","volume":"32","author":"Zhang","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"115946","DOI":"10.1016\/j.bmc.2020.115946","article-title":"Methods to generate site-specific conjugates of antibody and protein","volume":"30","author":"Park","year":"2021","journal-title":"Bioorg. Med. Chem."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"14852","DOI":"10.1021\/acs.jmedchem.4c00802","article-title":"Structure-Activity Relationship of Antibody-Oligonucleotide Conjugates: Evaluating Bioconjugation Strategies for Antibody-siRNA Conjugates for Drug Development","volume":"67","author":"Cochran","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.hoc.2022.08.015","article-title":"Current and Emerging Role of Antibody-Drug Conjugates in HER2-Negative Breast Cancer","volume":"37","author":"Abelman","year":"2023","journal-title":"Hematol. Oncol. Clin. N. Am."},{"key":"ref_49","doi-asserted-by":"crossref","unstructured":"Hammood, M., Craig, A.W., and Leyton, J.V. (2021). Impact of Endocytosis Mechanisms for the Receptors Targeted by the Currently Approved Antibody-Drug Conjugates (ADCs)-A Necessity for Future ADC Research and Development. Pharmaceuticals, 14.","DOI":"10.3390\/ph14070674"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"5135","DOI":"10.2147\/DDDT.S344052","article-title":"Dynamics of Endocytosis and Degradation of Antibody-Drug Conjugate T-DM1 in HER2 Positive Cancer Cells","volume":"15","author":"Liang","year":"2021","journal-title":"Drug Des. Devel. Ther."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"11561","DOI":"10.1038\/s41598-022-15838-8","article-title":"Synchronous intracellular delivery of EGFR-targeted antibody-drug conjugates by p38-mediated non-canonical endocytosis","volume":"12","author":"Takahashi","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"25798","DOI":"10.1021\/acsomega.0c03102","article-title":"cIRCR201-dPBD, a Novel Pyrrolobenzodiazepine Dimer-Containing Site-Specific Antibody-Drug Conjugate Targeting c-Met Overexpression Tumors","volume":"5","author":"Min","year":"2020","journal-title":"ACS Omega"},{"key":"ref_53","first-page":"12929","article-title":"Conjugating MMAE to a novel anti-HER2 antibody for selective targeted delivery","volume":"24","author":"Li","year":"2020","journal-title":"Eur. Rev. Med. Pharmacol. Sci."},{"key":"ref_54","first-page":"e2400173","article-title":"Antibody-Drug Conjugates in Breast Cancer: Toward a Molecular Perspective Into Clinical Practice","volume":"8","author":"Pinto","year":"2024","journal-title":"JCO Precis. Oncol."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jconrel.2024.08.049","article-title":"Optimization of a pendant-shaped PEGylated linker for antibody-drug conjugates","volume":"375","author":"Tedeschini","year":"2024","journal-title":"J. Control. Release"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"114063","DOI":"10.1016\/j.ejmech.2021.114063","article-title":"Dual intra- and extracellular release of monomethyl auristatin E from a neutrophil elastase-sensitive antibody-drug conjugate","volume":"229","author":"Huvelle","year":"2022","journal-title":"Eur. J. Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"41783","DOI":"10.1021\/acsomega.5c05758","article-title":"Comparative Enzymatic and Stability Assays Reveal GPLG as an Effective Cathepsin B Cleavable Linker for Tumor-Targeting Drug Conjugates","volume":"10","author":"Cazzaniga","year":"2025","journal-title":"ACS Omega"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"1860","DOI":"10.1021\/acs.bioconjchem.2c00314","article-title":"A Novel Family of Acid-Cleavable Linker Based on Cyclic Acetal Motifs for the Production of Antibody-Drug Conjugates with High Potency and Selectivity","volume":"33","author":"Rady","year":"2022","journal-title":"Bioconjug. Chem."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"7578","DOI":"10.1021\/jacs.4c16842","article-title":"Fluorogenic Platform for Real-Time Imaging of Subcellular Payload Release in Antibody-Drug Conjugates","volume":"147","author":"Salomon","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1021\/acs.bioconjchem.1c00435","article-title":"Prostate-Specific Membrane Antigen-Targeted Turn-on Probe for Imaging Cargo Release in Prostate Cancer Cells","volume":"32","author":"Olatunji","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"5284","DOI":"10.1021\/jacs.1c07675","article-title":"Single Mutation on Trastuzumab Modulates the Stability of Antibody-Drug Conjugates Built Using Acetal-Based Linkers and Thiol-Maleimide Chemistry","volume":"144","author":"Ferhati","year":"2022","journal-title":"J. Am. Chem. Soc."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"118088","DOI":"10.1016\/j.bmc.2025.118088","article-title":"Fine-tuning phenoxy silyl scaffolds for the development of glutathione-responsive prodrugs and antibody-drug conjugates","volume":"120","author":"Wei","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"e10388","DOI":"10.1002\/btm2.10388","article-title":"Near-infrared-induced drug release from antibody-drug double conjugates exerts a cytotoxic photo-bystander effect","volume":"7","author":"Takahashi","year":"2022","journal-title":"Bioeng. Transl. Med."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1021\/acs.bioconjchem.2c00174","article-title":"Radiation Cleaved Drug-Conjugate Linkers Enable Local Payload Release","volume":"33","author":"Quintana","year":"2022","journal-title":"Bioconjug. Chem."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"e2500305","DOI":"10.1002\/cbic.202500305","article-title":"Advanced Antibody-Drug Conjugates Design: Innovation in Linker Chemistry and Site-Specific Conjugation Technologies","volume":"26","author":"Matsuda","year":"2025","journal-title":"ChemBioChem"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.hemonc.2021.07.002","article-title":"Therapeutic Roles of Antibody Drug Conjugates (ADCs) in Relapsed\/Refractory Lymphomas","volume":"16","author":"Hashmi","year":"2023","journal-title":"Hematol. Oncol. Stem Cell Ther."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/1535-7163.MCT-21-0693","article-title":"Comparison of Pyrrolobenzodiazepine Dimer Bis-imine versus Mono-imine: DNA Interstrand Cross-linking, Cytotoxicity, Antibody-Drug Conjugate Efficacy and Toxicity","volume":"22","author":"Tiberghien","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1038\/s41571-023-00850-2","article-title":"Exploring the next generation of antibody-drug conjugates","volume":"21","author":"Tsuchikama","year":"2024","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Long, R., Zuo, H., Tang, G., Zhang, C., Yue, X., Yang, J., Luo, X., Deng, Y., Qiu, J., and Li, J. (2025). Antibody-drug conjugates in cancer therapy: Applications and future advances. Front. Immunol., 16.","DOI":"10.3389\/fimmu.2025.1516419"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1038\/s41419-024-06665-y","article-title":"A potential strategy for bladder cancer treatment: Inhibiting autophagy to enhance antitumor effects of Nectin-4-MMAE","volume":"15","author":"Wang","year":"2024","journal-title":"Cell Death Dis."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"100279","DOI":"10.1016\/j.xcrm.2021.100279","article-title":"NOTCH3-targeted antibody drug conjugates regress tumors by inducing apoptosis in receptor cells and through transendocytosis into ligand cells","volume":"2","author":"Geles","year":"2021","journal-title":"Cell Rep. Med."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"e006274","DOI":"10.1136\/jitc-2022-006274","article-title":"An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer","volume":"11","author":"Wittwer","year":"2023","journal-title":"J. Immunother. Cancer"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"148101","DOI":"10.1016\/j.ijbiomac.2025.148101","article-title":"Antibody-DNA nanostructure conjugates exhibit inhibited effects on CT26 cells and prevent upregulation of PD-1 in the tumor microenvironment","volume":"330","author":"Li","year":"2025","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"103012","DOI":"10.1016\/j.ctrv.2025.103012","article-title":"Combining antibody-drug conjugates with immune checkpoint inhibitors: A new paradigm for breast cancer therapy","volume":"140","author":"Xu","year":"2025","journal-title":"Cancer Treat. Rev."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s10238-025-01655-6","article-title":"Mechanism of action and future perspectives of ADCs in combination with immune checkpoint inhibitors for solid tumors","volume":"25","author":"Lv","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"124","DOI":"10.3892\/or.2025.8956","article-title":"Breaking therapeutic barriers in solid tumors: Clinical progress of antibody-drug conjugate\/immune checkpoint inhibitor combinations (Review)","volume":"54","author":"Zheng","year":"2025","journal-title":"Oncol. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"118010","DOI":"10.1016\/j.bmc.2024.118010","article-title":"The journey of antibody-drug conjugates for revolutionizing cancer therapy: A review","volume":"117","author":"Akram","year":"2025","journal-title":"Bioorg. Med. Chem."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1158\/1535-7163.MCT-20-0287","article-title":"HDP-101, an Anti-BCMA Antibody-Drug Conjugate, Safely Delivers Amanitin to Induce Cell Death in Proliferating and Resting Multiple Myeloma Cells","volume":"20","author":"Ko","year":"2021","journal-title":"Mol. Cancer Ther."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1016\/j.apsb.2024.12.036","article-title":"Resistance to antibody-drug conjugates: A review","volume":"15","author":"Li","year":"2025","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"101086","DOI":"10.1016\/j.drup.2024.101086","article-title":"Spotlight on ideal target antigens and resistance in antibody-drug conjugates: Strategies for competitive advancement","volume":"75","author":"Jiang","year":"2024","journal-title":"Drug Resist. Updat."},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1186\/s13045-025-01752-9","article-title":"Overcoming resistance to antibody-drug conjugates: From mechanistic insights to cutting-edge strategies","volume":"18","author":"Zhou","year":"2025","journal-title":"J. Hematol. Oncol."},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"101353","DOI":"10.1016\/j.drup.2026.101353","article-title":"Mechanisms of resistance to antibody-drug conjugates in breast cancer","volume":"85","author":"Cerci","year":"2026","journal-title":"Drug Resist. Updat."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"2310890","DOI":"10.1080\/19420862.2024.2310890","article-title":"Biparatopic antibodies: Therapeutic applications and prospects","volume":"16","author":"Niquille","year":"2024","journal-title":"mAbs"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"8735","DOI":"10.1038\/s41598-025-92697-z","article-title":"Preclinical evaluation of a novel antibody-drug conjugate OBI-992 for Cancer therapy","volume":"15","author":"Chang","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1038\/s41598-024-84566-y","article-title":"A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan","volume":"15","author":"Ito","year":"2025","journal-title":"Sci. Rep."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"2362454","DOI":"10.1080\/2162402X.2024.2362454","article-title":"CD20 expression regulates CD37 levels in B-cell lymphoma\u2014Implications for immunotherapies","volume":"13","author":"Bobrowicz","year":"2024","journal-title":"Oncoimmunology"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"6427","DOI":"10.1038\/s41467-021-26018-z","article-title":"RAB5A expression is a predictive biomarker for trastuzumab emtansine in breast cancer","volume":"12","author":"Engebraaten","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"17588359251332473","DOI":"10.1177\/17588359251332473","article-title":"The mechanisms of HER2 targeted ADCs are dependent on Rab GTPases","volume":"17","author":"Medhus","year":"2025","journal-title":"Ther. Adv. Med. Oncol."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"10258","DOI":"10.1111\/jcmm.15643","article-title":"Hsp90 inhibition and co-incubation with pertuzumab induce internalization and degradation of trastuzumab: Implications for use of T-DM1","volume":"24","author":"Skeie","year":"2020","journal-title":"J. Cell Mol. Med."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1158\/2159-8290.CD-20-0215","article-title":"HER2-Mediated Internalization of Cytotoxic Agents in ERBB2 Amplified or Mutant Lung Cancers","volume":"10","author":"Li","year":"2020","journal-title":"Cancer Discov."},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"101792","DOI":"10.1016\/j.xcrm.2024.101792","article-title":"EGFR-directed antibodies promote HER2 ADC internalization and efficacy","volume":"5","author":"Gupta","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"117184","DOI":"10.1016\/j.bios.2025.117184","article-title":"Cathepsin B dependent activatable trigger fluorophore (CAT-Fluor) for in situ functional imaging of antibody-drug conjugates","volume":"274","author":"Ning","year":"2025","journal-title":"Biosens. Bioelectron."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"pgac063","DOI":"10.1093\/pnasnexus\/pgac063","article-title":"SLC46A3 is a lysosomal proton-coupled steroid conjugate and bile acid transporter involved in transport of active catabolites of T-DM1","volume":"1","author":"Tomabechi","year":"2022","journal-title":"PNAS Nexus"},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1021\/acs.molpharmaceut.2c00741","article-title":"Identification of 5-Carboxyfluorescein as a Probe Substrate of SLC46A3 and Its Application in a Fluorescence-Based In Vitro Assay Evaluating the Interaction with SLC46A3","volume":"20","author":"Tomabechi","year":"2023","journal-title":"Mol. Pharm."},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1021\/acs.bioconjchem.1c00029","article-title":"Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody-Drug Conjugates","volume":"32","author":"Chuprakov","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1039\/D3MD00569K","article-title":"Linker substitution influences succinimide ring hydrolysis equilibrium impacting the stability of attachment to antibody-drug conjugates","volume":"15","author":"Wang","year":"2024","journal-title":"RSC Med. Chem."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"18124","DOI":"10.1021\/acs.jmedchem.4c01251","article-title":"Exo-Cleavable Linkers: Enhanced Stability and Therapeutic Efficacy in Antibody-Drug Conjugates","volume":"67","author":"Watanabe","year":"2024","journal-title":"J. Med. Chem."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1021\/acs.bioconjchem.4c00348","article-title":"Linker and Conjugation Site Synergy in Antibody-Drug Conjugates: Impacts on Biological Activity","volume":"35","author":"Aoyama","year":"2024","journal-title":"Bioconjug. Chem."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.jconrel.2021.07.041","article-title":"Polyethylene glycol-based linkers as hydrophilicity reservoir for antibody-drug conjugates","volume":"337","author":"Tedeschini","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1021\/acs.bioconjchem.4c00392","article-title":"PEGylation of Dipeptide Linker Improves Therapeutic Index and Pharmacokinetics of Antibody-Drug Conjugates","volume":"36","author":"Long","year":"2025","journal-title":"Bioconjug. Chem."},{"key":"ref_101","doi-asserted-by":"crossref","unstructured":"Roth, J.S., Guo, H., Chen, L., Shen, M., Gbadegesin, O., Robey, R.W., Gottesman, M.M., and Hall, M.D. (2025). Identification of antibody-drug conjugate payloads which are substrates of ATP-binding cassette drug efflux transporters. bioRxiv.","DOI":"10.1101\/2025.05.22.651305"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"101310","DOI":"10.1016\/j.drup.2025.101310","article-title":"Beyond the boundary: The emerging roles of ATP-binding cassette transporters in multidrug resistance (MDR) and therapeutic targeting in cancer","volume":"84","author":"Sun","year":"2025","journal-title":"Drug Resist. Updat."},{"key":"ref_103","doi-asserted-by":"crossref","unstructured":"Yalamarty, S.S.K., Filipczak, N., Li, X., Pathrikar, T.V., Cotter, C., and Torchilin, V.P. (2022). Co-Delivery of siRNA and Chemotherapeutic Drug Using 2C5 Antibody-Targeted Dendrimer-Based Mixed Micelles for Multidrug Resistant Cancers. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14071470"},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Tashima, T. (2022). Brain Cancer Chemotherapy through a Delivery System across the Blood-Brain Barrier into the Brain Based on Receptor-Mediated Transcytosis Using Monoclonal Antibody Conjugates. Biomedicines, 10.","DOI":"10.3390\/biomedicines10071597"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1124\/dmd.123.001516","article-title":"Preclinical Characterization of Catabolic Pathways and Metabolism of ABBV-011, a Novel Calicheamicin-Based SEZ6-Targeting Antibody-Drug Conjugate","volume":"52","author":"Ladror","year":"2024","journal-title":"Drug Metab. Dispos."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1097\/CCO.0000000000001065","article-title":"Update of antibody-drug conjugates for hematological malignancies","volume":"36","author":"Sun","year":"2024","journal-title":"Curr. Opin. Oncol."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1056\/NEJMra1406184","article-title":"Acute Myeloid Leukemia","volume":"373","author":"Weisdorf","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"101286","DOI":"10.1016\/j.drup.2025.101286","article-title":"Targeted therapy in acute myeloid leukemia: Resistance and overcoming strategy","volume":"83","author":"Song","year":"2025","journal-title":"Drug Resist. Updat."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1182\/blood-2017-09-797712","article-title":"Gemtuzumab ozogamicin for acute myeloid leukemia","volume":"130","author":"Appelbaum","year":"2017","journal-title":"Blood"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1158\/1078-0432.CCR-11-0486","article-title":"Antibody-drug conjugates of calicheamicin derivative: Gemtuzumab ozogamicin and inotuzumab ozogamicin","volume":"17","author":"Ricart","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1182\/blood-2013-01-466706","article-title":"A phase 3 study of gemtuzumab ozogamicin during induction and postconsolidation therapy in younger patients with acute myeloid leukemia","volume":"121","author":"Petersdorf","year":"2013","journal-title":"Blood"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"113","DOI":"10.3324\/haematol.2018.188888","article-title":"Gemtuzumab ozogamicin for de novo acute myeloid leukemia: Final efficacy and safety updates from the open-label, phase III ALFA-0701 trial","volume":"104","author":"Lambert","year":"2019","journal-title":"Haematologica"},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2474","DOI":"10.1002\/cncr.32116","article-title":"Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: Final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study","volume":"125","author":"Kantarjian","year":"2019","journal-title":"Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1200\/JCO.23.00546","article-title":"Inotuzumab Ozogamicin as Induction Therapy for Patients Older Than 55 Years With Philadelphia Chromosome-Negative B-Precursor ALL","volume":"42","author":"Stelljes","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/s13045-024-01552-7","article-title":"Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: Past progress, current research and future directions","volume":"17","author":"Short","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1007\/s40259-017-0254-1","article-title":"Recent Developments in ADC Technology: Preclinical Studies Signal Future Clinical Trends","volume":"31","author":"Drake","year":"2017","journal-title":"BioDrugs"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1093\/jnci\/djz035","article-title":"Antibody-Drug Conjugate-Based Therapeutics: State of the Science","volume":"111","author":"Birrer","year":"2019","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1158\/2326-6066.CIR-13-0198","article-title":"Microtubule-depolymerizing agents used in antibody-drug conjugates induce antitumor immunity by stimulation of dendritic cells","volume":"2","author":"Martin","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1158\/1535-7163.MCT-23-0118","article-title":"Brentuximab Vedotin-Driven Microtubule Disruption Results in Endoplasmic Reticulum Stress Leading to Immunogenic Cell Death and Antitumor Immunity","volume":"23","author":"Heiser","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"2183","DOI":"10.1200\/JCO.2011.38.0410","article-title":"Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin\u2019s lymphoma","volume":"30","author":"Younes","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1016\/S0140-6736(15)60165-9","article-title":"Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin\u2019s lymphoma at risk of relapse or progression (AETHERA): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"385","author":"Moskowitz","year":"2015","journal-title":"Lancet"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood.2019003127","article-title":"Brentuximab vedotin with chemotherapy for stage III\/IV classical Hodgkin lymphoma: 3-year update of the ECHELON-1 study","volume":"135","author":"Straus","year":"2020","journal-title":"Blood"},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1200\/JCO-24-02242","article-title":"Brentuximab Vedotin Combination for Relapsed Diffuse Large B-Cell Lymphoma","volume":"43","author":"Bartlett","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1007\/s40265-019-01175-0","article-title":"Polatuzumab Vedotin: First Global Approval","volume":"79","author":"Deeks","year":"2019","journal-title":"Drugs"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1056\/NEJMoa2115304","article-title":"Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell Lymphoma","volume":"386","author":"Tilly","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41591-023-02726-5","article-title":"Mosunetuzumab with polatuzumab vedotin in relapsed or refractory aggressive large B cell lymphoma: A phase 1b\/2 trial","volume":"30","author":"Budde","year":"2024","journal-title":"Nat. Med."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1186\/2162-3619-1-36","article-title":"CD19: A biomarker for B cell development, lymphoma diagnosis and therapy","volume":"1","author":"Wang","year":"2012","journal-title":"Exp. Hematol. Oncol."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1182\/blood-2017-10-813493","article-title":"ADCT-402, a PBD dimer-containing antibody drug conjugate targeting CD19-expressing malignancies","volume":"131","author":"Zammarchi","year":"2018","journal-title":"Blood"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1016\/S1470-2045(21)00139-X","article-title":"Loncastuximab tesirine in relapsed or refractory diffuse large B-cell lymphoma (LOTIS-2): A multicentre, open-label, single-arm, phase 2 trial","volume":"22","author":"Caimi","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"e23","DOI":"10.1016\/S2352-3026(24)00345-4","article-title":"Loncastuximab tesirine with rituximab in patients with relapsed or refractory follicular lymphoma: A single-centre, single-arm, phase 2 trial","volume":"12","author":"Alderuccio","year":"2025","journal-title":"Lancet Haematol."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1158\/1535-7163.MCT-23-0506","article-title":"ADCT-602, a Novel PBD Dimer-containing Antibody-Drug Conjugate for Treating CD22-positive Hematologic Malignancies","volume":"23","author":"Zammarchi","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_132","doi-asserted-by":"crossref","unstructured":"Kirchhoff, D., Stelte-Ludwig, B., Lerchen, H.G., Wengner, A.M., Ahsen, O.V., Buchmann, P., M\u00e4rsch, S., Mahlert, C., Greven, S., and Dietz, L. (2020). IL3RA-Targeting Antibody-Drug Conjugate BAY-943 with a Kinesin Spindle Protein Inhibitor Payload Shows Efficacy in Preclinical Models of Hematologic Malignancies. Cancers, 12.","DOI":"10.3390\/cancers12113464"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"1768","DOI":"10.1038\/s41375-018-0210-1","article-title":"Moxetumomab pasudotox in relapsed\/refractory hairy cell leukemia","volume":"32","author":"Kreitman","year":"2018","journal-title":"Leukemia"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/S1470-2045(20)30756-7","article-title":"Treatment of relapsed and refractory multiple myeloma: Recommendations from the International Myeloma Working Group","volume":"22","author":"Moreau","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1002\/ijc.33002","article-title":"B-cell maturation antigen-specific chimeric antigen receptor T cells for multiple myeloma: Clinical experience and future perspectives","volume":"147","author":"Sellner","year":"2020","journal-title":"Int. J. Cancer"},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e801","DOI":"10.1016\/S2352-3026(23)00243-0","article-title":"Efficacy and safety of single-agent belantamab mafodotin versus pomalidomide plus low-dose dexamethasone in patients with relapsed or refractory multiple myeloma (DREAMM-3): A phase 3, open-label, randomised study","volume":"10","author":"Dimopoulos","year":"2023","journal-title":"Lancet Haematol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1038\/s41408-024-01135-2","article-title":"Belantamab mafodotin, pomalidomide, and dexamethasone for triple class exposed\/refractory relapsed multiple myeloma: A subgroup analysis of the ALGONQUIN trial","volume":"14","author":"McCurdy","year":"2024","journal-title":"Blood Cancer J."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1158\/1535-7163.MCT-23-0482","article-title":"Biomarkers for Antibody-Drug Conjugates in Solid Tumors","volume":"23","author":"Katrini","year":"2024","journal-title":"Mol. Cancer Ther."},{"key":"ref_139","doi-asserted-by":"crossref","unstructured":"Kondrashov, A., Sapkota, S., Sharma, A., Riano, I., Kurzrock, R., and Adashek, J.J. (2023). Antibody-Drug Conjugates in Solid Tumor Oncology: An Effectiveness Payday with a Targeted Payload. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15082160"},{"key":"ref_140","first-page":"165","article-title":"Antibody-drug conjugates: Smart chemotherapy delivery across tumor histologies","volume":"72","author":"Tarantino","year":"2022","journal-title":"CA Cancer J. Clin."},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"e390094","DOI":"10.1200\/EDBK_390094","article-title":"Rise of Antibody-Drug Conjugates: The Present and Future","volume":"43","author":"Shastry","year":"2023","journal-title":"Am. Soc. Clin. Oncol. Educ. Book"},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"1143","DOI":"10.1056\/NEJMoa2115022","article-title":"Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer","volume":"386","author":"Kim","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2110","DOI":"10.1056\/NEJMoa2407086","article-title":"Trastuzumab Deruxtecan after Endocrine Therapy in Metastatic Breast Cancer","volume":"391","author":"Bardia","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1186\/bcr3621","article-title":"Trastuzumab emtansine: Mechanisms of action and drug resistance","volume":"16","author":"Barok","year":"2014","journal-title":"Breast Cancer Res."},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"1529","DOI":"10.1056\/NEJMoa2028485","article-title":"Sacituzumab Govitecan in Metastatic Triple-Negative Breast Cancer","volume":"384","author":"Bardia","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.1016\/S0140-6736(23)01245-X","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): A randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo","year":"2023","journal-title":"Lancet"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"2134","DOI":"10.1002\/ijc.34424","article-title":"A Phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments","volume":"152","author":"Xu","year":"2023","journal-title":"Int. J. Cancer"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1200\/JCO.24.00920","article-title":"Datopotamab Deruxtecan Versus Chemotherapy in Previously Treated Inoperable\/Metastatic Hormone Receptor-Positive Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer: Primary Results From TROPION-Breast01","volume":"43","author":"Bardia","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1200\/JCO.23.01909","article-title":"Datopotamab Deruxtecan in Advanced or Metastatic HR+\/HER2\u2212 and Triple-Negative Breast Cancer: Results from the Phase I TROPION-PanTumor01 Study","volume":"42","author":"Bardia","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1158\/1535-7163.MCT-22-0786","article-title":"Discovery and Preclinical Characterization of XMT-1660, an Optimized B7-H4-Targeted Antibody-Drug Conjugate for the Treatment of Cancer","volume":"22","author":"Toader","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1038\/s41591-025-03600-2","article-title":"A B7H3-targeting antibody-drug conjugate in advanced solid tumors: A phase 1\/1b trial","volume":"31","author":"Ma","year":"2025","journal-title":"Nat. Med."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.2174\/0109298673358929250213093803","article-title":"HER3-targeting Antibody-drug Conjugates Therapy for Solid Tumors: Recent Advances and Future Potentials","volume":"32","author":"Wang","year":"2025","journal-title":"Curr. Med. Chem."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13045-021-01035-z","article-title":"Antibody-drug conjugates in solid tumors: A look into novel targets","volume":"14","author":"Criscitiello","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s40364-022-00416-x","article-title":"HER2-targeted advanced metastatic gastric\/gastroesophageal junction adenocarcinoma: Treatment landscape and future perspectives","volume":"10","author":"Li","year":"2022","journal-title":"Biomark. Res."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"2419","DOI":"10.1056\/NEJMoa2004413","article-title":"Trastuzumab Deruxtecan in Previously Treated HER2-Positive Gastric Cancer","volume":"382","author":"Shitara","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S1470-2045(24)00380-2","article-title":"Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): Primary results from a multicentre, randomised, phase 2 trial","volume":"25","author":"Raghav","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1002\/cac2.12214","article-title":"Efficacy and safety of a novel anti-HER2 therapeutic antibody RC48 in patients with HER2-overexpressing, locally advanced or metastatic gastric or gastroesophageal junction cancer: A single-arm phase II study","volume":"41","author":"Peng","year":"2021","journal-title":"Cancer Commun."},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"101710","DOI":"10.1016\/j.xcrm.2024.101710","article-title":"CMG901, a Claudin18.2-specific antibody-drug conjugate, for the treatment of solid tumors","volume":"5","author":"Xu","year":"2024","journal-title":"Cell Rep. Med."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1186\/s13045-024-01595-w","article-title":"Targeting Claudin-18.2 for cancer therapy: Updates from 2024 ASCO annual meeting","volume":"17","author":"Zhou","year":"2024","journal-title":"J. Hematol. Oncol."},{"key":"ref_162","doi-asserted-by":"crossref","first-page":"3003","DOI":"10.1158\/0008-5472.CAN-15-1313","article-title":"Enfortumab Vedotin Antibody-Drug Conjugate Targeting Nectin-4 Is a Highly Potent Therapeutic Agent in Multiple Preclinical Cancer Models","volume":"76","author":"Satpayev","year":"2016","journal-title":"Cancer Res."},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1158\/1078-0432.CCR-24-1393","article-title":"FDA Approval Summary: Enfortumab Vedotin plus Pembrolizumab for Locally Advanced or Metastatic Urothelial Carcinoma","volume":"30","author":"Brave","year":"2024","journal-title":"Clin. Cancer Res."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"2592","DOI":"10.1200\/JCO.19.01140","article-title":"Pivotal Trial of Enfortumab Vedotin in Urothelial Carcinoma After Platinum and Anti-Programmed Death 1\/Programmed Death Ligand 1 Therapy","volume":"37","author":"Rosenberg","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1056\/NEJMoa2035807","article-title":"Enfortumab Vedotin in Previously Treated Advanced Urothelial Carcinoma","volume":"384","author":"Powles","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1056\/NEJMoa2312117","article-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","volume":"390","author":"Powles","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.22.01643","article-title":"Enfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer","volume":"41","author":"Hoimes","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_168","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1016\/j.annonc.2021.03.005","article-title":"Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: Final safety and efficacy results from the phase I\/II IMMU-132-01 basket trial","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_169","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.annonc.2025.01.011","article-title":"Sacituzumab govitecan in advanced urothelial carcinoma: TROPiCS-04, a phase III randomized trial","volume":"36","author":"Powles","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/S1470-2045(21)00056-5","article-title":"Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204\/GOG-3023\/ENGOT-cx6): A multicentre, open-label, single-arm, phase 2 study","volume":"22","author":"Coleman","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1056\/NEJMoa2313811","article-title":"Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer","volume":"391","author":"Vergote","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"5536","DOI":"10.1200\/JCO.23.00720","article-title":"Tisotumab Vedotin in Combination with Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results from the innovaTV 205\/GOG-3024\/ENGOT-cx8 Study","volume":"41","author":"Vergote","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S1470-2045(18)30859-3","article-title":"Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): A first-in-human, multicentre, phase 1-2 trial","volume":"20","author":"Concin","year":"2019","journal-title":"Lancet Oncol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"2436","DOI":"10.1200\/JCO.22.01900","article-title":"Efficacy and Safety of Mirvetuximab Soravtansine in Patients with Platinum-Resistant Ovarian Cancer with High Folate Receptor Alpha Expression: Results from the SORAYA Study","volume":"41","author":"Matulonis","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_175","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.annonc.2024.11.011","article-title":"The efficacy and safety of mirvetuximab soravtansine in FR\u03b1-positive, third-line and later, recurrent platinum-sensitive ovarian cancer: The single-arm phase II PICCOLO trial","volume":"36","author":"Lewin","year":"2025","journal-title":"Ann. Oncol."},{"key":"ref_176","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1080\/14712598.2021.1869210","article-title":"Novel mesothelin antibody-drug conjugates: Current evidence and future role in the treatment of ovarian cancer","volume":"21","author":"Mauricio","year":"2021","journal-title":"Expert. Opin. Biol. Ther."},{"key":"ref_177","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1158\/1535-7163.MCT-22-0322","article-title":"Discovery of STRO-002, a Novel Homogeneous ADC Targeting Folate Receptor Alpha, for the Treatment of Ovarian and Endometrial Cancers","volume":"22","author":"Li","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Jiang, Y., Xu, Y., He, J., Sui, L., Li, T., Xia, N., and Yao, Q. (2025). Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1525733"},{"key":"ref_179","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2025.03.011","article-title":"Diagnostic and therapeutic advances for HER2-expressing or amplified gynecologic cancers","volume":"195","author":"Lee","year":"2025","journal-title":"Gynecol. Oncol."},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Buza, N. (2025). The Rapidly Evolving Landscape of Human Epidermal Growth Factor Receptor 2 (HER2) Testing in Endometrial Carcinoma and Other Gynecologic Malignancies. Arch. Pathol. Lab. Med.","DOI":"10.5858\/arpa.2025-0046-RA"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"4099","DOI":"10.1002\/cncr.30869","article-title":"HER2 mutations in lung adenocarcinomas: A report from the Lung Cancer Mutation Consortium","volume":"123","author":"Pillai","year":"2017","journal-title":"Cancer"},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1470-2045(25)00012-9","article-title":"Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): Phase 2 results from a multicentre, single-arm study","volume":"26","author":"Li","year":"2025","journal-title":"Lancet Oncol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1038\/s41392-024-01897-y","article-title":"SHR-A1811 (antibody-drug conjugate) in advanced HER2-mutant non-small cell lung cancer: A multicenter, open-label, phase 1\/2 study","volume":"9","author":"Li","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"260","DOI":"10.1200\/JCO-24-01544","article-title":"Datopotamab Deruxtecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III TROPION-Lung01 Study","volume":"43","author":"Ahn","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1200\/JCO-24-01349","article-title":"Datopotamab Deruxtecan in Advanced or Metastatic Non-Small Cell Lung Cancer with Actionable Genomic Alterations: Results from the Phase II TROPION-Lung05 Study","volume":"43","author":"Sands","year":"2025","journal-title":"J. Clin. Oncol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"2860","DOI":"10.1200\/JCO.24.00733","article-title":"Sacituzumab Govitecan Versus Docetaxel for Previously Treated Advanced or Metastatic Non-Small Cell Lung Cancer: The Randomized, Open-Label Phase III EVOKE-01 Study","volume":"42","author":"Mountzios","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"3000","DOI":"10.1200\/JCO.24.00720","article-title":"Telisotuzumab Vedotin Monotherapy in Patients with Previously Treated c-Met Protein-Overexpressing Advanced Nonsquamous EGFR-Wildtype Non-Small Cell Lung Cancer in the Phase II LUMINOSITY Trial","volume":"42","author":"Camidge","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1182\/blood-2014-09-598763","article-title":"Brentuximab vedotin demonstrates objective responses in a phase 2 study of relapsed\/refractory DLBCL with variable CD30 expression","volume":"125","author":"Jacobsen","year":"2015","journal-title":"Blood"},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.annonc.2021.06.002","article-title":"Biomarker analyses in the phase III ASCENT study of sacituzumab govitecan versus chemotherapy in patients with metastatic triple-negative breast cancer","volume":"32","author":"Bardia","year":"2021","journal-title":"Ann. Oncol."},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1158\/1078-0432.CCR-22-1764","article-title":"Membranous NECTIN-4 Expression Frequently Decreases during Metastatic Spread of Urothelial Carcinoma and Is Associated with Enfortumab Vedotin Resistance","volume":"29","author":"Ralser","year":"2023","journal-title":"Clin. Cancer Res."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"816","DOI":"10.1200\/JCO.22.00575","article-title":"Trastuzumab Deruxtecan in Anti-Human Epidermal Growth Factor Receptor 2 Treatment-Naive Patients with Human Epidermal Growth Factor Receptor 2-Low Gastric or Gastroesophageal Junction Adenocarcinoma: Exploratory Cohort Results in a Phase II Trial","volume":"41","author":"Yamaguchi","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_192","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1038\/nrd.2016.268","article-title":"Strategies and challenges for the next generation of antibody-drug conjugates","volume":"16","author":"Beck","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"5441","DOI":"10.1158\/1078-0432.CCR-19-0272","article-title":"Antibody-Drug Conjugates: Future Directions in Clinical and Translational Strategies to Improve the Therapeutic Index","volume":"25","author":"Coats","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"ref_194","first-page":"155","article-title":"Affinity and avidity in antibody-based tumor targeting","volume":"24","author":"Rudnick","year":"2009","journal-title":"Cancer Biother. Radiopharm."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1158\/0008-5472.CAN-06-2531","article-title":"Imaging tumors with an albumin-binding Fab, a novel tumor-targeting agent","volume":"67","author":"Dennis","year":"2007","journal-title":"Cancer Res."},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/j.ccell.2022.09.016","article-title":"The therapeutic window of antibody drug conjugates: A dogma in need of revision","volume":"40","author":"Colombo","year":"2022","journal-title":"Cancer Cell"},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"4212","DOI":"10.1158\/1078-0432.CCR-22-0456","article-title":"Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer","volume":"28","author":"Zhang","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_198","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1158\/1078-0432.CCR-21-3261","article-title":"Anti-CD79B Antibody-Drug Conjugate DCDS0780A in Patients with B-Cell Non-Hodgkin Lymphoma: Phase 1 Dose-Escalation Study","volume":"28","author":"Herrera","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_199","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1158\/1535-7163.MCT-22-0145","article-title":"Efficacy, Tolerability, and Pharmacokinetic Studies of Antibody-Drug Conjugates Containing a Low-Potency Pyrrolobenzodiazepine Dimer","volume":"21","author":"Gregson","year":"2022","journal-title":"Mol. Cancer Ther."},{"key":"ref_200","doi-asserted-by":"crossref","first-page":"pkad069","DOI":"10.1093\/jncics\/pkad069","article-title":"Toxicity profiles of antibody-drug conjugates for anticancer treatment: A systematic review and meta-analysis","volume":"7","author":"Suzuki","year":"2023","journal-title":"JNCI Cancer Spectr."},{"key":"ref_201","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1038\/s41571-023-00783-w","article-title":"Optimizing the safety of antibody-drug conjugates for patients with solid tumours","volume":"20","author":"Tarantino","year":"2023","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_202","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/s10549-020-05754-8","article-title":"Incidence of pneumonitis\/interstitial lung disease induced by HER2-targeting therapy for HER2-positive metastatic breast cancer","volume":"183","author":"Hackshaw","year":"2020","journal-title":"Breast Cancer Res. Treat."},{"key":"ref_203","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s11095-021-03158-x","article-title":"Fc\u03b3 Receptor-Dependent Internalization and Off-Target Cytotoxicity of Antibody-Drug Conjugate Aggregates","volume":"39","author":"Aoyama","year":"2022","journal-title":"Pharm. Res."},{"key":"ref_204","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1002\/cac2.12387","article-title":"Resistance to antibody-drug conjugates in breast cancer: Mechanisms and solutions","volume":"43","author":"Chen","year":"2023","journal-title":"Cancer Commun."},{"key":"ref_205","doi-asserted-by":"crossref","unstructured":"Balamkundu, S., and Liu, C.F. (2023). Lysosomal-Cleavable Peptide Linkers in Antibody-Drug Conjugates. Biomedicines, 11.","DOI":"10.20944\/preprints202305.1084.v1"},{"key":"ref_206","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.resinv.2025.05.012","article-title":"Mechanisms of resistance to antibody-drug conjugates in cancers","volume":"63","author":"Murase","year":"2025","journal-title":"Respir. Investig."},{"key":"ref_207","doi-asserted-by":"crossref","first-page":"e957","DOI":"10.1093\/oncolo\/oyae055","article-title":"Optimal Sequential Strategies for Antibody-Drug Conjugate in Metastatic Breast Cancer: Evaluating Efficacy and Cross-Resistance","volume":"29","author":"Chen","year":"2024","journal-title":"Oncologist"},{"key":"ref_208","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1038\/s41416-024-02766-9","article-title":"Efficacy of administration sequence: Sacituzumab Govitecan and Trastuzumab Deruxtecan in HER2-low metastatic breast cancer","volume":"131","author":"Poumeaud","year":"2024","journal-title":"Br. J. Cancer"},{"key":"ref_209","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1007\/s11912-024-01582-x","article-title":"Economics of Antibody Drug Conjugates (ADCs): Innovation, Investment and Market Dynamics","volume":"26","author":"Bhushan","year":"2024","journal-title":"Curr. Oncol. Rep."},{"key":"ref_210","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s11095-023-03649-z","article-title":"Antibody-Drug Conjugate Overview: A State-of-the-art Manufacturing Process and Control Strategy","volume":"41","author":"Li","year":"2024","journal-title":"Pharm. Res."},{"key":"ref_211","doi-asserted-by":"crossref","first-page":"2965","DOI":"10.1016\/j.xphs.2023.09.007","article-title":"CMC Regulatory Considerations for Antibody-Drug Conjugates","volume":"112","author":"Ruggiero","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"ref_212","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1038\/d41573-021-00054-2","article-title":"The oncology market for antibody-drug conjugates","volume":"20","author":"Nawaz","year":"2021","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_213","doi-asserted-by":"crossref","first-page":"3434","DOI":"10.1016\/j.xphs.2024.10.002","article-title":"Review of dose justifications for antibody-drug conjugate approvals from clinical pharmacology perspective: A focus on exposure-response analyses","volume":"113","author":"Hu","year":"2024","journal-title":"J. Pharm. Sci."},{"key":"ref_214","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1016\/S1470-2045(24)00159-1","article-title":"BL-B01D1, a first-in-class EGFR-HER3 bispecific antibody-drug conjugate, in patients with locally advanced or metastatic solid tumours: A first-in-human, open-label, multicentre, phase 1 study","volume":"25","author":"Ma","year":"2024","journal-title":"Lancet Oncol."},{"key":"ref_215","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/s41570-020-00241-6","article-title":"The renaissance of chemically generated bispecific antibodies","volume":"5","author":"Szijj","year":"2021","journal-title":"Nat. Rev. Chem."},{"key":"ref_216","doi-asserted-by":"crossref","first-page":"984","DOI":"10.1158\/1078-0432.CCR-19-1457","article-title":"Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology","volume":"26","author":"Autio","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"ref_217","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1158\/1078-0432.CCR-21-3656","article-title":"Praluzatamab Ravtansine, a CD166-Targeting Antibody-Drug Conjugate, in Patients with Advanced Solid Tumors: An Open-Label Phase I\/II Trial","volume":"28","author":"Boni","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"ref_218","doi-asserted-by":"crossref","unstructured":"Pronk, S.D., Schooten, E., Heinen, J., Helfrich, E., Oliveira, S., and van Bergen En Henegouwen, P.M.P. (2021). Single Domain Antibodies as Carriers for Intracellular Drug Delivery: A Proof of Principle Study. Biomolecules, 11.","DOI":"10.3390\/biom11070927"},{"key":"ref_219","doi-asserted-by":"crossref","first-page":"4145","DOI":"10.1158\/0008-5472.CAN-20-3822","article-title":"Transient Competitive Inhibition Bypasses the Binding Site Barrier to Improve Tumor Penetration of Trastuzumab and Enhance T-DM1 Efficacy","volume":"81","author":"Bordeau","year":"2021","journal-title":"Cancer Res."},{"key":"ref_220","doi-asserted-by":"crossref","first-page":"5667","DOI":"10.1038\/s41467-020-19498-y","article-title":"Co-administered antibody improves penetration of antibody-dye conjugate into human cancers with implications for antibody-drug conjugates","volume":"11","author":"Lu","year":"2020","journal-title":"Nat. Commun."},{"key":"ref_221","doi-asserted-by":"crossref","first-page":"e202310318","DOI":"10.1002\/anie.202310318","article-title":"Azobenzene-Based Linker Strategy for Selective Activation of Antibody-Drug Conjugates","volume":"63","author":"Xiao","year":"2024","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_222","doi-asserted-by":"crossref","first-page":"25914","DOI":"10.1002\/anie.202109835","article-title":"Diazaborines Are a Versatile Platform to Develop ROS-Responsive Antibody Drug Conjugates","volume":"60","author":"Carvalho","year":"2021","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_223","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1248\/bpb.b19-00864","article-title":"Surface Modification of Liposomes Using IR700 Enables Efficient Controlled Contents Release Triggered by Near-IR Light","volume":"43","author":"Kono","year":"2020","journal-title":"Biol. Pharm. Bull."},{"key":"ref_224","doi-asserted-by":"crossref","first-page":"20957","DOI":"10.1021\/jacs.5c04942","article-title":"Silicon Rhodamine-Catalyzed Near-Infrared Light-Induced Photodecaging of Ortho-Nitrobenzyl Groups In Vitro and In Vivo","volume":"147","author":"Yan","year":"2025","journal-title":"J. Am. Chem. Soc."},{"key":"ref_225","doi-asserted-by":"crossref","unstructured":"Miyazaki, N.L., Furusawa, A., Choyke, P.L., and Kobayashi, H. (2023). Review of RM-1929 Near-Infrared Photoimmunotherapy Clinical Efficacy for Unresectable and\/or Recurrent Head and Neck Squamous Cell Carcinoma. Cancers, 15.","DOI":"10.3390\/cancers15215117"},{"key":"ref_226","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41467-018-03880-y","article-title":"Chemically triggered drug release from an antibody-drug conjugate leads to potent antitumour activity in mice","volume":"9","author":"Rossin","year":"2018","journal-title":"Nat. Commun."},{"key":"ref_227","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1021\/acs.bioconjchem.1c00342","article-title":"Precision Modification of Native Antibodies","volume":"32","author":"Wu","year":"2021","journal-title":"Bioconjug. Chem."},{"key":"ref_228","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1038\/nbt.3212","article-title":"Reducing hydrophobicity of homogeneous antibody-drug conjugates improves pharmacokinetics and therapeutic index","volume":"33","author":"Lyon","year":"2015","journal-title":"Nat. Biotechnol."},{"key":"ref_229","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1038\/s43018-020-00136-x","article-title":"Immune-stimulating antibody conjugates elicit robust myeloid activation and durable antitumor immunity","volume":"2","author":"Ackerman","year":"2021","journal-title":"Nat. Cancer"},{"key":"ref_230","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1158\/1078-0432.CCR-24-2449","article-title":"XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Induces Innate Antitumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells","volume":"31","author":"Bukhalid","year":"2025","journal-title":"Clin. Cancer Res."},{"key":"ref_231","doi-asserted-by":"crossref","first-page":"e004704","DOI":"10.1136\/jitc-2022-004704","article-title":"GPC2 antibody-drug conjugate reprograms the neuroblastoma immune milieu to enhance macrophage-driven therapies","volume":"10","author":"McIntyre","year":"2022","journal-title":"J. Immunother. Cancer"},{"key":"ref_232","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1158\/1078-0432.CCR-21-1621","article-title":"BCMA-Specific ADC MEDI2228 and Daratumumab Induce Synergistic Myeloma Cytotoxicity via IFN-Driven Immune Responses and Enhanced CD38 Expression","volume":"27","author":"Xing","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"ref_233","doi-asserted-by":"crossref","first-page":"113719","DOI":"10.1016\/j.jconrel.2025.113719","article-title":"Advancements in delivery Systems for Proteolysis-Targeting Chimeras (PROTACs): Overcoming challenges and expanding biomedical applications","volume":"382","author":"Yu","year":"2025","journal-title":"J. Control. Release"},{"key":"ref_234","doi-asserted-by":"crossref","first-page":"2685","DOI":"10.1007\/s00259-025-07103-7","article-title":"Radiotheranostic landscape: A review of clinical and preclinical development","volume":"52","author":"Tran","year":"2025","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"ref_235","doi-asserted-by":"crossref","unstructured":"Wilski, N.A., Haytko, P., Zha, Z., Wu, S., Jin, Y., Chen, P., Han, C., and Chiu, M.L. (2025). A Dual-Payload Bispecific ADC Improved Potency and Efficacy over Single-Payload Bispecific ADCs. Pharmaceutics, 17.","DOI":"10.3390\/pharmaceutics17080967"},{"key":"ref_236","doi-asserted-by":"crossref","first-page":"1334","DOI":"10.1021\/acsmedchemlett.5c00209","article-title":"Homogeneous Dual-Payload Antibody-Drug Conjugates Produced by Combined Distinct Conjugation Strategies","volume":"16","author":"Watanabe","year":"2025","journal-title":"ACS Med. Chem. Lett."},{"key":"ref_237","doi-asserted-by":"crossref","first-page":"2498162","DOI":"10.1080\/19420862.2025.2498162","article-title":"Homogeneous antibody-drug conjugates with dual payloads: Potential, methods and considerations","volume":"17","author":"Wen","year":"2025","journal-title":"mAbs"},{"key":"ref_238","doi-asserted-by":"crossref","first-page":"3528","DOI":"10.1038\/s41467-021-23793-7","article-title":"Antibody-drug conjugates with dual payloads for combating breast tumor heterogeneity and drug resistance","volume":"12","author":"Yamazaki","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_239","doi-asserted-by":"crossref","first-page":"3848","DOI":"10.1158\/0008-5472.CAN-23-4099","article-title":"A Dual-Payload Antibody-Drug Conjugate Targeting CD276\/B7-H3 Elicits Cytotoxicity and Immune Activation in Triple-Negative Breast Cancer","volume":"84","author":"Zhou","year":"2024","journal-title":"Cancer Res."},{"key":"ref_240","doi-asserted-by":"crossref","unstructured":"Kocabey, S., Ekim Kocabey, A., Schneiter, R., and R\u00fcegg, C. (2021). Membrane-Interacting DNA Nanotubes Induce Cancer Cell Death. Nanomaterials, 11.","DOI":"10.3390\/nano11082003"},{"key":"ref_241","doi-asserted-by":"crossref","first-page":"e00047","DOI":"10.1002\/mabi.202500047","article-title":"Evaluation of HER2 Targeted Poly(Ethylene Glycol)-Poly(L-histidine) Copolymer Micelles in Breast Cancer Models","volume":"25","author":"Pandya","year":"2025","journal-title":"Macromol. Biosci."},{"key":"ref_242","doi-asserted-by":"crossref","unstructured":"Thakur, C.K., Karthikeyan, C., Ashby, C.R., Neupane, R., Singh, V., Babu, R.J., Narayana Moorthy, N.S.H., and Tiwari, A.K. (2024). Ligand-conjugated multiwalled carbon nanotubes for cancer targeted drug delivery. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1417399"},{"key":"ref_243","doi-asserted-by":"crossref","unstructured":"Kuwatani, M., and Sakamoto, N. (2023). Promising Highly Targeted Therapies for Cholangiocarcinoma: A Review and Future Perspectives. Cancers, 15.","DOI":"10.3390\/cancers15143686"},{"key":"ref_244","doi-asserted-by":"crossref","first-page":"129348","DOI":"10.1016\/j.bmcl.2023.129348","article-title":"Generation and structure-activity relationships of novel imidazo-thienopyridine based TLR7 agonists: Application as payloads for immunostimulatory antibody drug-conjugates","volume":"91","author":"Brant","year":"2023","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_245","doi-asserted-by":"crossref","first-page":"19088","DOI":"10.1021\/jacs.4c03529","article-title":"On Demand Bioorthogonal Switching of an Antibody-Conjugated SPECT Probe to a Cytotoxic Payload: From Imaging to Therapy","volume":"146","author":"Adhikari","year":"2024","journal-title":"J. Am. Chem. Soc."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/2\/324\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T05:26:02Z","timestamp":1772083562000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/19\/2\/324"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,15]]},"references-count":245,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2026,2]]}},"alternative-id":["ph19020324"],"URL":"https:\/\/doi.org\/10.3390\/ph19020324","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,15]]}}}